Cargando…
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly under...
Autores principales: | Breeksema, Joost J., Niemeijer, Alistair, Kuin, Bouwe, Veraart, Jolien, Kamphuis, Jeanine, Schimmel, Nina, van den Brink, Wim, Vermetten, Eric, Schoevers, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732097/ https://www.ncbi.nlm.nih.gov/pubmed/36506427 http://dx.doi.org/10.3389/fpsyt.2022.948115 |
Ejemplares similares
-
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
por: Breeksema, Joost J., et al.
Publicado: (2023) -
Adverse events in clinical treatments with serotonergic psychedelics
and MDMA: A mixed-methods systematic review
por: Breeksema, Joost J, et al.
Publicado: (2022) -
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
por: Breeksema, Joost J., et al.
Publicado: (2020) -
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022) -
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2021)